U.S. Markets closed

Conatus Pharma to explore options, liver disease drug fails trial

June 24 (Reuters) - Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options.

Separately, the company said it is discontinuing the development of its liver disease drug, emricasan, after it failed to meet the main goal in a mid-stage study. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)